Abstract
Objective: Drug incompatibilities can compromise the safety and effectiveness of parenteral therapy. The aim of this study was to identify combinations of parenteral drugs that are prescribed in primary care and to analyze their potential for incompatibilities. Methods: A pilot cross-sectional study was conducted at the Health Center "Novi Sad". Data on patients and drugs were collected from electronic health records. The potential for incompatibilities was analyzed at the level of drug pairs and in accordance with data in three literature sources. Results: In total, 196 drug pairs were identified: 56 (28.6%) were compatible, 16 (8.2%) were incompatible and compatibility was unknown for 124 (63.3%) pairs. Among incompatible pairs, 87.5% (14/16) were prescribed for intravenous administration. Pantoprazole was most often included in potential incompatibilities. Among the pairs of unknown compatibility, 80.6% (100/124) were prescribed for intramuscular administration and mainly included Dexamethasone, diclofenac, hydroxocobalamin and Diazepam. Conclusion: Taking into account the frequency and risks of potential incompatibilities, proposing guidelines to their avoiding would be useful.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference33 articles.
1. World Health Organization. Technical Series on Safer Primary Care: Medication errors. Geneva: World Health Organization, 2016. (https://www.who.int/ publications/item/9789241511643);
2. Puzovic M, Morrissey H, Bali PA. Parenteral therapy in domiciliary and outpatient setting: a critical review of the literature. Arch Pharm Pract 2023; 14: 1-12;
3. Haidar NA, AlAmri MN, Manthattil FL, AlShaof MA, AlKuhali SM. Outcome and complications of outpatient parenteral therapy in pediatric emergency utilizing only peripheral vascular access. Saudi Med J 2023; 44: 1047-53;
4. Berland A, Bentsen SB. Medication errors in home care: a qualitative focus group study. J Clin Nurs 2017; 26: 3734-41;
5. Pericà S JM, LIopis J, González-Ramallo V, et al. Outpatient parenteral antibiotic treatment (OPAT) for infective endocarditis: a prospective cohort study from the GAMES cohort. Clin Infect Dis 2019; 69: 1690-700;